{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.11","value":"-10.9"},{"groupId":"OG001","spread":"26.22","value":"-11.0"}]}],"title":"Loss of Appetite (n=473, 471)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.86","value":"-12.1"},{"groupId":"OG001","spread":"27.29","value":"-12.0"}]}],"title":"Fatigue (n=473, 472)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.28","value":"-13.8"},{"groupId":"OG001","spread":"26.28","value":"-14.3"}]}],"title":"Cough (n=476, 473)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.01","value":"-11.0"},{"groupId":"OG001","spread":"24.31","value":"-10.5"}]}],"title":"Dyspnea (n=472, 477)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.89","value":"-1.4"},{"groupId":"OG001","spread":"8.79","value":"-1.1"}]}],"title":"Hemoptysis (n=475, 475)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.62","value":"-11.3"},{"groupId":"OG001","spread":"24.85","value":"-11.5"}]}],"title":"Pain (n=476, 475)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.37","value":"-10.7"},{"groupId":"OG001","spread":"26.25","value":"-12.2"}]}],"title":"Symptom Distress (n=474, 472)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.13","value":"-8.5"},{"groupId":"OG001","spread":"24.95","value":"-7.9"}]}],"title":"Interference With Activity Level (n=474, 472)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.68","value":"-10.4"},{"groupId":"OG001","spread":"23.23","value":"-8.9"}]}],"title":"Global Quality of Life (n=467, 469)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.75","value":"-6.1"},{"groupId":"OG001","spread":"14.50","value":"-6.9"}]}],"title":"ASBI (n=455, 456)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.75","value":"-5.2"},{"groupId":"OG001","spread":"14.66","value":"-6.4"}]}],"title":"Total LCSS (n=446, 446)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"477"}],"units":"Participants"}],"description":"The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \\[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\\] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.","dispersionType":"Standard Deviation","groups":[{"description":"On Day 1 of each 21-day cycle, participants received ramucirumab DP followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Ramucirumab DP: 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG000","title":"Ramucirumab and Docetaxel"},{"description":"On Day 1 of each 21-day cycle, participants received placebo followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Placebo (matching Ramucirumab DP): 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG001","title":"Placebo and Docetaxel"}],"paramType":"MEAN","populationDescription":"Randomized participants grouped according to their assigned treatment at randomization, who had a baseline and at least 1 post-baseline LCSS score.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 21 of each cycle, and 30 days following last infusion (up to Cycle 38, 21 days/cycle)","title":"Maximum Improvement on Lung Cancer Symptom Scale (LCSS)","type":"SECONDARY","unitOfMeasure":"mm"}